FORM 4				OMB APPROV	VAL	
Check this box if no longer subject to Se Form 4 or Form 5 obligations may continstruction 1(b).  Check this box to indicate that a transac made pursuant to a contract, instruction plan for the purchase or sale of equity se the issuer that is intended to satisfy the defense conditions of Rule 10b5-1(c). Second 10.  [Print or Type Responses]	inue. See tion was or written securities of Filed pursuan affirmative	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES ant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940				
1. Name and Address of Reporting Person * Nisen Perry D.		2. Issuer Name and Ticker or Trading Symbol Teva Pharmaceutical Industries Limited [ TEVA ]	5. Relationship of Reporting  X Director	(Check all applicable)		
(Last) (First) C/O Teva Pharmaceutical Industries Ltd. 124 Dvora HaNevi'a St.,	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 06/05/2025	Officer (give title bel	rector 10% Owner cer (give title below) Other (specify below)		
(Street) Tel Aviv, L3 6944020		4. If Amendment, Date Original Filed (Month/Day/Year)	_ X _ Form filed by One Re	Filing (Check Applicable Line) porting Person n One Reporting Person		
(City) (State)	(Zip)	7				

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

	1.Title of Security (Instr. 3)	Date (Month	Execution	Code		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	Ownership Form:	Beneficial
				Code	V	Amount	(A) or (D)	Price			Ownership (Instr. 4)
ĺ	Ordinary Shares (1)	06/06/2025		М		9,632	A	(2)	105,315	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month /Day/Year)	3A. Deemed Execution Date, if any (Month/Day /Year)	4. Transact Code (Instr. 8)	ion	Derivative Securities D		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	of Derivative Securities Beneficially	Ownership Form of Derivative Security:	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Following Reported	Direct (D) or Indirect (I) (Instr. 4)	
Restricted Share Units	(2)	06/06/2025		М			9,632	(3)	(3)	Ordinary Shares <sup>(1)</sup>	9,632	\$ 0	0	D	
Restricted Share Units	(2)	06/05/2025		A		14,492		(4)	(4)	Ordinary Shares <sup>(1)</sup>	14,492	\$ 0	14,492	D	

## **Explanation of Responses:**

- 1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- 2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- 3. Restricted share units were granted on June 6, 2024 and vested on June 6, 2025.
- 4. Restricted share units were granted on June 5, 2025 and vest on June 5, 2026.



Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.